Ovid Therapeutics Inc. (OVID)

Market Cap	336.28M +811.3%
Revenue (ttm)	6.61M +945.9%
Net Income	-35.87M
EPS	-0.50
Shares Out	131.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,982,757
Open	2.560
Previous Close	2.620
Day's Range	2.460 - 2.685
52-Week Range	0.243 - 2.720
Beta	0.16
Analysts	Strong Buy
Price Target	4.20 (+64.71%)
Earnings Date	Mar 18, 2026

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's d...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 5, 2017
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: OVID
• Website: https://www.ovidrx.com

Financial Performance

In 2024, Ovid Therapeutics's revenue was $566,000, an increase of 44.39% compared to the previous year's $392,000. Losses were -$25.98 million, -49.49% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price target is $4.2, which is an increase of 64.71% from the latest price.

Price Target

$4.2

(64.71% upside)

Analyst Consensus: Strong Buy